Publications by authors named "Lori A Cox"
Article Synopsis
- A post-hoc analysis of the ALLEGRO study assessed the effects of ritlecitinib, an oral JAK inhibitor, in treating patients aged 12 and older with alopecia totalis (AT) and alopecia universalis (AU) over 48 weeks.
- Out of 718 patients, those treated with ritlecitinib showed significantly higher hair regrowth response rates compared to the placebo group, improving from week 24 to week 48.
- Ritlecitinib was well tolerated, demonstrating clinical efficacy and an acceptable safety profile for patients with both AT and AU.
Article Synopsis
- A phase 2b trial evaluated the effectiveness of ritlecitinib, a JAK3/TEC kinase inhibitor, in treating patients with active non-segmental vitiligo, comparing different dosages against a placebo over 24 weeks.
- Active vitiligo lesions showed higher levels of inflammatory markers compared to stable lesions, and patients with more active lesions had elevated serum levels of specific biomarkers.
- After 24 weeks, the 50 mg dose of ritlecitinib significantly reduced depigmentation and increased repigmentation in stable lesions, while also influencing immune response markers in both active and stable lesions.
Article Synopsis
- Vitiligo is a chronic autoimmune condition that leads to skin depigmentation, and this study aimed to assess the effectiveness and safety of ritlecitinib, a JAK3/TEC inhibitor, in treating active nonsegmental vitiligo in a phase 2b trial.
- The trial involved 364 patients who received various doses of ritlecitinib or a placebo over 24 weeks, with improvements in vitiligo severity significantly noted in those taking ritlecitinib compared to placebo.
- Ultimately, the study concluded that ritlecitinib was both effective and well-tolerated for 48 weeks, although it excluded patients with stable vitiligo.
Article Synopsis
- The ALLEGRO phase 2a trial investigated the safety and effectiveness of two drugs, ritlecitinib and brepocitinib, for treating alopecia areata over a 24-week period, followed by an additional extension phase for patients who did not respond adequately.
- A total of 18 patients switched from ritlecitinib to brepocitinib, while 5 switched the other way, with no new safety concerns reported post-crossover.
- An exploratory analysis indicated that some patients switched to brepocitinib showed significant improvement in hair loss severity, suggesting potential benefits for those not responding to ritlecitinib, though firm conclusions are limited due to the small sample size.
Article Synopsis
- Janus kinase (JAK) inhibitors, specifically ritlecitinib and brepocitinib, are being studied for treating alopecia areata (AA) with promising results from early research.
- In a phase 2a clinical trial, biopsy samples from 46 patients showed significant improvements in scalp biomarkers after 24 weeks, correlating with hair regrowth measured by the Severity of Alopecia Tool (SALT) score.
- While brepocitinib showed better results at week 12, ritlecitinib outperformed it by week 24, suggesting the need for larger and longer-term trials to confirm these findings.
Article Synopsis
- Alopecia areata (AA) is a type of hair loss caused by the immune system, and this study aimed to test the effectiveness of two drugs, ritlecitinib and brepocitinib, in patients with significant scalp hair loss.
- In a 24-week trial, both drugs showed a significant improvement in hair regrowth compared to a placebo, with brepocitinib being more effective than ritlecitinib.
- The treatments were generally well tolerated, although there was a case of a serious side effect (rhabdomyolysis) in the brepocitinib group.
The levels of 63 cytokines, chemokines, and growth factors were measured in the serum of four patients with idiopathic morphea and of one patient with vitamin K-induced morphea employing a multiplex assay to identify the role of inflammatory/immunologic events in their pathogenesis. Full-thickness skin biopsies of affected skin were analyzed by histopathology. Luminex assays for 63 cytokines, chemokines, and growth factors were performed in the sera from four patients with idiopathic morphea and in two different samples of serum obtained in two separate occasions from one patient with vitamin K-induced morphea.
View Article and Find Full Text PDFObjective: For healthcare providers, witnessed cardiopulmonary resuscitation (CPR) is controversial. However, little is known about the public's stance on this issue. This study was performed to develop insight concerning the general public's thoughts about witnessed CPR.
View Article and Find Full Text PDFRecent studies have demonstrated the presence of microchimeric cells in peripheral blood and skin lesions from patients with systemic sclerosis (SSc). In a previous study we found that some peripheral blood CD3+ cells from female patients with SSc contained male DNA. Here, peripheral blood samples from 47 patients with SSc (30 with diffuse cutaneous SSc and 17 with limited cutaneous SSc) and 22 healthy controls were sorted for CD4+ and CD8+ T cells.
View Article and Find Full Text PDF